The two companies announced Monday that Novartis’ Alcon eye care division would commercialize and license the technology, which was designed by the Google X development team.

“We are looking forward to working with Google to bring together their advanced technology and our extensive knowledge of biology to meet unmet medical needs,” said Joe Jimenez, chief executive of Novartis.